سعر ارموويك 50مجم 20 قرص 2024

Armowake 50 mg 20 tablets: armodafinil 50 mg tablets, a wakefulness-promoting agent (R-enantiomer of modafinil), by Eva Pharma, Egypt; pack of 20 tablets.

• to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnoea (OSA), narcolepsy or shift work disorder (SWD); in OSA it treats sleepiness, not the underlying obstruction.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (5% or more and more than placebo): headache, nausea, dizziness and insomnia. Others (1% or more) include anxiety, diarrhoea, dry mouth, depression, dyspepsia, fatigue, palpitations, rash and upper abdominal pain.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Postmarketing: mouth sores including blistering and ulceration.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to modafinil, armodafinil or any inactive ingredient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious rash including Stevens-Johnson syndrome and toxic epidermal necrolysis has been reported; discontinue at the first sign of rash unless clearly not drug-related.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• DRESS/multi-organ hypersensitivity (including a fatal case), angioedema and anaphylaxis have been reported; discontinue if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Persistent sleepiness: wakefulness may not return to normal; reassess sleepiness and advise avoiding driving or dangerous activities where appropriate.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Steroidal (hormonal) contraceptives, e.g. ethinylestradiolEffectiveness may be reduced during treatment and for one month after stopping; use alternative or additional non-hormonal contraception.DailyMed (U.S. National Library of Medicine)
• CYP3A4/5 substrates (e.g. ciclosporin, midazolam, triazolam)Clearance may be increased through enzyme induction, lowering exposure; consider dose adjustment and monitor ciclosporin levels.DailyMed (U.S. National Library of Medicine)
• CYP2C19 substrates (e.g. phenytoin, diazepam, propranolol, omeprazole, clomipramine)Elimination may be prolonged through enzyme inhibition, increasing exposure; dose reduction may be required.DailyMed (U.S. National Library of Medicine)

• Limited data in pregnant women are insufficient to inform drug-associated risk; intrauterine growth restriction and spontaneous abortion have been reported with armodafinil and modafinil; animal studies showed developmental toxicity at clinically relevant exposures. A US pregnancy exposure registry exists.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on armodafinil in human milk, effects on the breastfed infant or milk production (modafinil was present in rat milk); weigh the benefits of breastfeeding against the mother's need and potential infant risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Armodafinil: Mechanism of wakefulness promotion is unknown; armodafinil binds the dopamine transporter and inhibits dopamine reuptake (indirect dopamine agonist), with wake-promoting actions similar to sympathomimetics although its pharmacological profile is not identical.